AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

NASDAQ:MRNSMarinus Pharmaceuticals Stock Price, Forecast & News

$2.80
-0.27 (-8.79 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.80
Now: $2.80
$3.16
50-Day Range
$1.63
MA: $2.15
$3.18
52-Week Range
$0.77
Now: $2.80
$4.83
Volume1.37 million shs
Average Volume1.04 million shs
Market Capitalization$242.85 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors. It is also developing ganaxolone for cyclin-ependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, postpartum depression, refractory status epilepticus, and other indications. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Read More
Marinus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRNS
CUSIPN/A
Phone484-801-4670

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.50 per share

Profitability

Net Income$-54,120,000.00

Miscellaneous

Employees28
Market Cap$242.85 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.

Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

How has Marinus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Marinus Pharmaceuticals' stock was trading at $1.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MRNS shares have increased by 70.7% and is now trading at $2.80. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Marinus Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Marinus Pharmaceuticals.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Marinus Pharmaceuticals.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) posted its quarterly earnings results on Monday, May, 4th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.16. View Marinus Pharmaceuticals' earnings history.

What price target have analysts set for MRNS?

6 analysts have issued twelve-month target prices for Marinus Pharmaceuticals' shares. Their forecasts range from $1.70 to $6.00. On average, they expect Marinus Pharmaceuticals' share price to reach $4.87 in the next year. This suggests a possible upside of 73.8% from the stock's current price. View analysts' price targets for Marinus Pharmaceuticals.

What are Wall Street analysts saying about Marinus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Marinus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. " (3/20/2020)
  • 2. LADENBURG THALM/SH SH analysts commented, "We find this is the right and not completely unexpected decision considering his enthusiasm in developing ganaxolone, his broad experience in companies and as an investor, as well as the need for strong stewardship at this time." (8/9/2019)

Has Marinus Pharmaceuticals been receiving favorable news coverage?

Media headlines about MRNS stock have been trending extremely positive recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Marinus Pharmaceuticals earned a news impact score of 4.7 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutMarinus Pharmaceuticals.

Who are some of Marinus Pharmaceuticals' key competitors?

What other stocks do shareholders of Marinus Pharmaceuticals own?

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the following people:
  • Mr. Edward F. Smith, VP, CFO, Treasurer & Sec. (Age 48)
  • Mr. Christopher Michael Cashman, CEO, Pres & Director (Age 62)
  • Dr. Lorianne K. Masuoka, Chief Medical Officer (Age 58)
  • Dr. Scott Braunstein, Exec. Chairman (Age 56)
  • Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include VR Adviser LLC (7.50%), BlackRock Inc. (5.98%), Alyeska Investment Group L.P. (2.60%), JPMorgan Chase & Co. (1.71%), WINTON GROUP Ltd (1.53%) and State Street Corp (1.40%). Company insiders that own Marinus Pharmaceuticals stock include Christopher Michael Cashman, Edward F Smith and Scott Braunstein. View institutional ownership trends for Marinus Pharmaceuticals.

Which institutional investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, and Deutsche Bank AG. View insider buying and selling activity for Marinus Pharmaceuticals.

Which institutional investors are buying Marinus Pharmaceuticals stock?

MRNS stock was bought by a variety of institutional investors in the last quarter, including VR Adviser LLC, BlackRock Inc., JPMorgan Chase & Co., WINTON GROUP Ltd, Asymmetry Capital Management L.P., Geode Capital Management LLC, State Street Corp, and Nuveen Asset Management LLC. View insider buying and selling activity for Marinus Pharmaceuticals.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $2.80.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $242.85 million. The biopharmaceutical company earns $-54,120,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Marinus Pharmaceuticals employs 28 workers across the globe.

What is Marinus Pharmaceuticals' official website?

The official website for Marinus Pharmaceuticals is www.marinuspharma.com.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.